Paxman receives an initial order under contract for the provision of scalp cooling systems to the U.S. Department of Veterans Affairs (VA) for the National Precision Oncology Program (NPOP)
Kurs
-0,40%
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-14 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-19 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2025-05-16 | - | Årsstämma |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-08 | - | Extra Bolagsstämma 2025 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Following the announcement last month that Paxman has partnered with Capri Construction 426 LLC to secure the nationwide contract to deliver Paxman Scalp Cooling Systems to the VA's national healthcare network, an initial order has been received of a value in excess of US $1million.
The contract period has a base year and four option years spanning July 1, 2024, to June 30, 2029, and this first order covers 43 Paxman Scalp Cooling Systems and associated individual-use scalp cooling cap kits. The equipment roll-out will commence over the coming weeks and into Q4, with installations in 43 individual VA infusion clinics from the VA's national healthcare network across 17 states.
Richard Paxman, CEO commented, “We are delighted to have received this initial order from the VA, in partnership with Capri, to begin the first stage of nationwide support of Veterans across the United States in managing the important side-effect of chemotherapy-induced alopecia.”
Contacts
Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 5,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).
The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.